“We basically ran three tests in the COVID-19 test to detect three different genes of SARS-COV-2 – the virus that causes COVID-19. One of these genes shows us a “spike” protein in a virus. In the British strain, this gene mutates and creates a “signature” on our test results. Basically, the signature tells us that a patient may have a new variant of COVID-19, ”Christopher Doern, Ph.D., director of microbiology at VCU Health, said.
Many of the credit card offers that appear on the website are from credit card companies for which ThePointsGuy.com receives compensation. This compensation may affect how and where products appear on this site (including, for example, the order in which they appear). This site does not include all credit card companies or all available credit card offers. Take a look at us advertising policy page for more information.
Editorial Note: The opinions expressed here are those of the authors themselves, not those of any bank, credit card issuer, airline or hotel chain, and have not been reviewed, approved or endorsed by any of these entities.
“Our launches to Norway and Switzerland complement Manscaped’s European regional expansion, which is a real milestone for the brand,” said Casey Gee, senior international business manager at Manscaped. “We are proud to increase our presence in Europe and can’t wait to get our products into the hands of this sharp and savvy new consumer. This growth catapulted an exciting year as we worked across continents, offering only the best formulas and tools to as many people as possible on a global scale. “
Born in 2016 and based in California, the direct-to-consumer (DTC) men’s grooming company designs and develops products and equipment for groin and body care and hygiene. The brand’s bigger goal is to advance men by enhancing the grooming experience while opening up confidence.
Manscaped makes it easy to browse and shop online, plus offers free shipping straight to your door. The brand’s newest customers in Norway and Switzerland can learn more and purchase their care kits here.
FDA sends January 8th warning stated that a new strain of the coronavirus could cause a false negative result in a molecular COVID-19 test.
The agency said false negatives could occur in the COVID-19 molecular test if mutations occurred in the part of the coronavirus genome used by the test to detect infection.
At least 52 cases of the COVID-19 variant were first discovered in the UK has been identified in the US Another variant first discovered in South Africa has been detected in several cases in the UK, France, Switzerland, Japan, Austria and Zambia.
The FDA said it was working with test developers and evaluating all official molecular tests to see how effective they were against the COVID-19 variant, and said they believed the risk the variants would affect the overall testing accuracy was low.
“While these efforts continue, we are working with official test developers and reviewing incoming data to ensure that healthcare providers and clinical staff can quickly and accurately diagnose patients infected with SARS-CoV-2, including those with an emerging genetic variant. . At this time, we believe the data show that the currently approved COVID-19 vaccine may still be effective against this strain. The FDA will continue to inform healthcare providers and the public about new information as it becomes available, “said FDA commissioner Stephen Hahn, MD.
Tests that use multiple regions of the viral genome may be less affected by the mutated strain than tests that use only one region, the FDA said.
The agency named three specific tests – MesaBiotech Accula, TaqPath COVID-19 Combo Kit, and Linea COVID-19 Assay Kit – as potentially affected by the COVID-19 variant, but said the impact appeared insignificant. The FDA also said that the detection patterns the TaqPath and Linea tests use when certain genetic variants are present in the coronavirus could actually help identify new variants of the virus earlier, which would help reduce the spread of infection.
Read the full FDA warning here.
More articles on the supply chain:
Congress uses the COVID-19 test that the FDA warned could give false negative results
Don’t let the COVID-19 vaccine priority groups slow down vaccinations, said the general surgeon
10 hospitals looking for supply chain talent
© Copyright ASC COMMUNICATIONS 2021. Interested in CONNECTING or REPRINTING this content? Check out our policies with clicking here.
WASHINGTON (Reuters) – A group representing major US airlines on Monday backed a proposal by public health officials to implement a global testing program that requires testing negative before most international air passengers return to the United States, according to a letter seen by Reuters.
Airlines for America, which represents American Airlines, United Airlines, Delta Air Lines and other major carriers, also urged the Trump administration in a letter to Vice President Mike Pence “to move forward with a recommendation to lift current entry restrictions on travelers from Europe, the UK. Kingdom and Brazil as quickly as possible … along with the testing program. “
In November, Reuters reported that the White House was considering lifting restrictions barring most non-US citizens from traveling to the United States from the 26-member Schengen area allowing travel across open borders in Europe, Britain, Ireland and Brazil.
“We are confident that a well-planned program focused on increasing testing of travelers to the United States will continue this goal in a much more effective manner than the comprehensive travel restrictions currently in place,” the airline’s letter said.
The airline supports a proposal by the US Centers for Disease Control and Prevention (CDC) to implement “a global program that mandates testing for travelers to the United States,” the letter added.
A senior government official said the CDC’s proposal to expand international testing requirements faced significant opposition at the top levels of the administration, including in Pence’s office. The White House coronavirus task force is expected to meet on Tuesday and the matter is scheduled to be discussed, officials said.
The CDC on December 28 began requiring all airline passengers arriving from the UK – including US citizens – to test negative for COVID-19 within 72 hours of departure.
A CDC spokesman declined to comment on Monday but the agency said last week that “efforts are currently underway in the US to assess risk reduction associated with testing and other recommended countermeasures … and get some level of agreement on standards for the approach. aligned to test international air travel. “
Airlines are seeking at least 14 days before the new requirements take effect and “consideration of inadequate testing and availability of results in certain countries rather than overarching requirements worldwide is also required,” the letter said.
Starting Thursday, Canada will require air travelers aged five and over who have tested negative for COVID-19 prior to arrival.
Reporting by David Shepardson; Edited by Chris Reese, Nick Zieminski and David Gregorio
